MedPath

Denali Therapeutics Spinout Secures $200M in Funding

A spinout from Denali Therapeutics, backed by Arch, has successfully raised $200 million. The startup begins its journey with several assets acquired from Denali Therapeutics, marking a significant step in the neuro sector.

A new chapter begins for a Denali Therapeutics spinout, which has successfully raised $200 million in funding. This significant financial boost is backed by Arch, highlighting the confidence in the startup's potential in the neuro sector. The company starts its operations with several assets acquired from Denali Therapeutics, setting a solid foundation for its future endeavors.
In related news, Jasper Therapeutics faced a setback with a negative reaction to data for its hives drug, while Stoke Therapeutics has finalized its Phase 3 trial plans, indicating ongoing developments and challenges within the biopharmaceutical industry.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Tenvie Therapeutics Launches with $200M for Neurodegeneration Drug R&D; Sana Biotechnology Achieves Landmark in Type 1 Diabetes Transplant

Tenvie Therapeutics, backed by Arch Venture Partners and others, debuts with $200 million to develop drugs targeting neurodegenerative diseases.

Johnson & Johnson MedTech Temporarily Pauses U.S. Varipulse Cases

Johnson & Johnson MedTech has announced a temporary pause on all U.S. cases using its Varipulse pulsed field ablation (PFA) system starting January 5, as it investigates the root cause of four reported issues.

FDA Rejects Astellas' Izervay Update; Cytokinetics and Bayer Announce Aficamten Licensing Deal

The FDA rejected Astellas' request to update Izervay's prescribing information for bi-monthly injections due to a statistical matter, maintaining Apellis' dosing advantage.

Trace Neuroscience Launches with $101M to Tackle ALS Using Antisense Technology

Trace Neuroscience launched with $101 million in funding to develop genetic medicines for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease with limited treatment options.

Trace Neuroscience Launches with $101 Million to Target ALS via UNC13A Restoration

Trace Neuroscience launched with $101 million in Series A funding led by Third Rock Ventures to develop genetic medicines for neurodegenerative diseases, focusing on amyotrophic lateral sclerosis (ALS).

Tezspire Shows Promise in Chronic Rhinosinusitis Trial; Gilead Halts Trodelvy Lung Cancer Development

AstraZeneca and Amgen's Tezspire significantly reduced nasal congestion and polyp size in a Phase 3 trial for chronic rhinosinusitis, potentially expanding its approved uses.

Bicara Therapeutics and Zenas BioPharma Aim for $200 Million IPOs

Bicara Therapeutics plans a $200 million IPO to advance ficerafusp alfa, a bifunctional antibody targeting EGFR and TGF-β for solid tumors.

Denali Therapeutics Plans Accelerated Approval Filing for Tividenofusp Alfa in MPS II

Denali Therapeutics plans to submit a Biologics License Application (BLA) to the FDA in early 2025 for tividenofusp alfa (DNL310) to treat Mucopolysaccharidosis type II (MPS II).

Denali Therapeutics Announces Positive Clinical Updates and Financial Results for Q1 2024

Denali Therapeutics reported positive two-year clinical data for tividenofusp alfa in MPS II, showing sustained normalization of heparan sulfate in CSF and improvements in clinical outcomes.

Denali's Hunter Syndrome Candidate Receives FDA Orphan Drug and Rare Pediatric Disease Designations

Denali Therapeutics Inc. announced that its pipeline candidate, DNL310, has been granted orphan drug status and a rare pediatric disease designation by the FDA for the treatment of Hunter Syndrome, a rare lysosomal storage disease. The company plans to initiate a phase I/II study in 2020, following promising pre-clinical results.

Reference News

[1]
Denali Therapeutics spinout raises $200M as neuro ...
ground.news · Jan 8, 2025

An Arch-backed startup launched with assets from Denali Therapeutics. Jasper faced criticism over its hives drug data, w...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy